Skip to main content
Premium Trial:

Request an Annual Quote

SAS Launches Life Science Unit

NEW YORK, March 31 - SAS today announced the launch of a new business unit dedicated to the life sciences market.

 

The new Life Sciences Organization is led by Kecia Serwin, who was formerly a sales director at the company. It will support healthcare providers, health insurers, and pharmaceutical, biotechnology and medical device companies.

 

The company has already identified several projects that the Life Sciences Organization will oversee, including support for biomedical customers in complying with the Food and Drug Administration's 21 CFR Part 11 regulations for the authentication of electronic documents. To meet this demand, SAS said that the Life Sciences Organization has launched the so-called Migration, Integration, and Validation (MIV) project to identify and address migration, integration, and validation issues related to achieving CFR Part 11 compliance.

 

For further information, see the press release.

The Scan

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.

DNA Biobank Developed for French Kidney Donors, Recipients

The KiT-GENIE biobank described in the European Journal of Human Genetics contains DNA samples, genotyping profiles, immune patterns, and clinical features for thousands of kidney donors or transplant recipients in Nantes, France.

Cardiometabolic Disease May Have Distinct Associations With Microbial Metabolites in Blood, Gut

By analyzing gut microbes in combination with related metabolites in feces and blood, researchers in Nature Communications found distinct cardiometabolic disease relationships at each site.

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.